Current Report Filing (8-k)
January 17 2020 - 8:01AM
Edgar (US Regulatory)
0001270073
false
0001270073
2020-01-14
2020-01-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section
13 or 15(d) of the
Securities Exchange
Act of 1934
Date of report (Date
of earliest event reported): January 15, 2020
Intercept Pharmaceuticals, Inc.
(Exact Name of Registrant
as Specified in Charter)
Delaware
(State or Other Jurisdiction
of Incorporation)
|
001-35668
(Commission
File Number)
|
22-3868459
(IRS Employer
Identification No.)
|
10 Hudson Yards, 37th Floor
New York, NY 10001
(Address of Principal
Executive Offices and Zip Code)
Registrant’s
telephone number, including area code: (646) 747-1000
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.001
per share
|
|
ICPT
|
|
Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
On December 13, 2019, Intercept Pharmaceuticals, Inc. (the “Company”)
announced that the U.S. Food and Drug Administration (“FDA”) had notified the Company that it was tentatively scheduling
an advisory committee meeting relating to the Company’s New Drug Application (“NDA”) for obeticholic acid in
liver fibrosis due to NASH for April 22, 2020. Given that this tentative date for the advisory committee meeting would take place
after the previously announced March 26, 2020 Prescription Drug User Fee Act (“PDUFA”) target action date, the Company
anticipated that the FDA would notify it of an extension to the PDUFA target action date.
On January 15, 2020, the FDA notified the Company that, pursuant
to a major amendment, the FDA has extended the PDUFA target action date to June 26, 2020. This typical three-month extension provides
the time needed to accommodate the advisory committee meeting and for the FDA to complete its review of the Company’s NDA,
including additional information provided in response to FDA requests.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
INTERCEPT PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Sandip Kapadia
|
|
|
Name: Sandip Kapadia
|
|
|
Title: Chief Financial Officer and Treasurer
|
Date: January 17, 2020
Intercept Pharmaceuticals (NASDAQ:ICPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Intercept Pharmaceuticals (NASDAQ:ICPT)
Historical Stock Chart
From Sep 2023 to Sep 2024